# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mizuho Securities raises target for Boston Scientific, predicting double-digit growth in cardiology. Surge in Farapulse adoptio...
Mizuho analyst Anthony Petrone maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $85 to $90.
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:BSX) with a Overweight and raises the price target from $70 t...
Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $79 to $85.